Effects of the nonpeptide V1 vasopressin receptor antagonist SR49059 in hypertensive patients

Hypertension

Volumn 34, Issue 6, 1999, Pages 1293-1300

  Thibonnier, Marc ^a   Kilani, Ahmad ^a   Rahman, Mahboob ^a   DiBlasi, Tina Pilumeli ^a   Warner, Kelly ^a   Smith, Michael C ^a   Leenhardt, Anne Françoise ^b   Brouard, Rémi ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

Author keywords

Hypertension, essential; Nonpeptide antagonist; Osmoregulation; Vasopressins

Indexed keywords

PLACEBO; RELCOVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MALE; OSMOREGULATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VASODILATATION;

EID: 0033452792     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.6.1293     Document Type: Article

References (34)

1. 3-pituitary AVP, and oxytocin receptors. Prog Brain Res. 1998;119: 143-158.
2. Altura BM, Altura BT. Vascular smooth muscle and neurohypophyseal hormones. Fed Proc. 1977;36:1853-1860.
3. Johnston CI. Vasopressin in circulatory control and hypertension. J Hypertens. 1985;3:557-569.
4. Goldsmith SR. Vasopressin as vasopressor. Am J Med. 1987;82: 1213-1219.
5. Cowley AW Jr. Vasopressin in cardiovascular regulation. Int Rev Physiol. 1982;26:189-242.
6. Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68:1248-1284.
7. Sladek C, Blair ML, Sterling C, Mangiapane ML. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist. Hypertension. 1988;12:506-512.
8. 1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23:737-743.
9. Okada H, Suzuki H, Kanno Y, Yamamura Y, Saruta T. Chronic and selective vasopressin blockade in spontaneously hypertensive rats. Am J Physiol. 1994;267:R1467-R1471.
10. Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI. Attenuation of genetic hypertension after short-term vasopressin Via receptor antagonism. Hypertension. 1995;26:828-834.
11. Manning M, Sawyer WH. Antagonists of vasopressin and oxytocin: current status and future perspectives. In: Jamison SJR, ed. Vasopressin. Paris/Londres: John Libbey; 1991:297-310.
12. 1 receptor antagonist. Science. 1991;252: 572-574.
13. Yamamura Y, Ogawa H, Yamashita H. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2-receptor antagonist. Br J Pharmacol. 1992;105:787-792.
14. Serradeil-Le Gal C, Wagnon J, Guillon G, Garcia C, Lacour C, Cantau B, Guiraudou P, Christophe B, Barberis C, Villanova G, Nisato D, Maffrand JP, Jard S, Le Fur G. Biochemical and pharmacological properties of SR49059, a new potent, non-peptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92:224-231.
15. 1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. In: Zingg H, Bourque CW, Bichet DG, eds. Vasopressin and Oxytocin: Molecular, Cellular, and Clinical Advances. New York, NY: Plenum Press; 1998:455-465.
16. Weber R, Pechère-Bertschi A, Hayoz D, Gerc V, Brouard R, Lahmy JP, Brunner HR, Burnier M. Effects of SR-49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension. 1997;30:1121-1127.
17. Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Invest. 1985;76:1857-1864.
18. Burton R, Mummert M, Newton J, Brouard R, Wu D. Determination of SR 49059 in human plasma and urine by LC-APCI/MS/MS. J Pharm Biomed Analysis. 1997;15:1913-1922.
19. Bussien JP, Waeber B, Nussberger JMDS, Gavras H, Hofbauer K, Brunner HR. Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? Am J Physiol. 1984;246:H143-H147.
20. Waeber B, Nussberger J, Hofbauer KG, Nicod P, Brunner HR. Clinical studies with a vascular vasopressin antagonist. J Cardiovasc Pharmacol. 1986;8:S111-S116.
21. Papadoliopoulou-Diamandopoulou N, Papagalanis N, Gavras I, Gavras H. Vasopressin in end-stage renal disease: relationship to salt, catecholamines and renin activity. Clin Exp Theory Practice. 1987;A9: 1197-1208.
22. Ribeiro A. Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension. 1986;8(suppl I):I-169-I-73.
23. Ribeiro AB, Saad CI, Zanella T, Mulinari RA, Kohlman O, Gavras H. Vasopressin maintains blood pressure in diabetic orthostatic hypotension. Hypertension. 1988;11(suppl I):I-217-I-21.
24. De Paula RB, Plavnik FL, Rodrigues CIS, De A Rocha Neves F, Kohlman O, Ribeiro AB, Gavras I, Gavras H. Age and race determine vasopressin participation in upright blood pressure control in essential hypertension. Ann N Y Acad Sci. 1993;689:534-536.
25. Share L, Wang YX, Crofton JT. Gender differences in the actions of vasopressin. In: Saito T, Kurokawa K, Yoshida S. eds. Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Amsterdam: Elsevier Science; 1995:3-13.
26. Grossman A, Besser GM, Milles JJ, Baylis PH. Inhibition of vasopressin release in man by an opiate peptide. Lancet. 1980;2:1108-1110.
27. Lightman S, Langdon N, Forsling M. Effects of the opiate antagonist naloxone and the nekephalin analog DAMME on the vasopressin response to a hypertonic stimulus in man. J Clin Endocr Metab. 1980;51:1447-1479.
28. Bayliss PH, Robertson GL. Plasma vasopressin response to hypertonic saline infusion to assess posterior pituitary function. J R Soc Med. 1980;73:255-260.
29. Thibonnier M, Sassano P, Daufresne S, Corvol P, Ménard J. Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. Kidney Int. 1984;25:411-415.
30. Phillips EMG, Butler T, Baylis PH. Osmoregulation of vasopressin and thirst: comparison of 20% mannitol with 5% saline as osmotic stimulants in healthy man. Clin Endocrinol. 1994;41:207-212.
31. 1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions. Br J Obstet Gynaecol. 1997;104:471-477.
32. 1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocrinology. 1999;89:113-120.
33. Sladek CD, Blair MI, Mangiapane M. Evidence against a pressor role for vasopressin in spontaneous hypertension. Hypertension. 1987;9:332-338.
34. Hofbauer KG, Mah SC, Baum HP, Hänni H, Wood JM, Kraetz J. Endocrine control of salt and water excretion: the role of vasopressin in DOCA-salt hypertension. J Cardiovasc Pharmacol. 1984;6: S184-S191.